Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology (Q39027803)

8 September 2017

title

Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology (English)

1 reference

8 September 2017

1 reference

Emanuel Stutz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490607%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Martin F Fey

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490607%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Mathias Gugger

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490607%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Sacha I Rothschild

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490607%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

1 February 2014

1 reference

8 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490607%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490607%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490607%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

211-217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490607%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

ALK, lung cancer, and personalized therapy: portent of the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Integrin-regulated FAK-Src signaling in normal and cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

The protein Id: a negative regulator of helix-loop-helix DNA binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.179

21 January 2018

Identifiers

DOI

10.2217/FON.13.179

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490607%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference